Professional
Added to YB: 2024-09-12
Pitch date: 2024-06-30
ALNY [bullish]
Alnylam Pharmaceuticals, Inc.
+63.13%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
Market Cap
$52.5B
Pitch Price
$240.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
136.16
P/E
1.2K
EV/Sales
16.38
Sector
Biotechnology
Category
value
Show full summary:
Loomis Sayles Global Growth Fund Portfolio Holding: Alnylam Pharmaceuticals, Inc.
ALNY: Leader in siRNA therapies with 5 approved drugs & 10+ in trials. Strong moat from RNAi expertise & partnerships. Positive Q2 results. HELIOS-B trial redesign for vutrisiran in ATTR-CM delayed but showed positive topline results. Undervalued due to market's narrow focus on near-term approval path.
Read full article (4 min)